A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors

Conditions:   Osteosarcoma;   Sarcoma;   Sarcoma,Soft Tissue;   Bone Tumor Intervention:   Drug: Recombinant oncolytic herpes simplex virus type Ⅰ (R130) Sponsors:   Shanghai Yunying Medical Technology;   Xi'an Honghui Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials